Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera Inc (NASDAQ: NTRA) delivers cutting-edge genetic testing solutions through its proprietary molecular diagnostics platform. This news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical research breakthroughs, and regulatory milestones.
Access official press releases alongside curated analysis of NTRA's innovations in non-invasive prenatal testing, oncology diagnostics, and transplant monitoring. Our repository tracks critical updates including quarterly earnings, partnership announcements, and peer-reviewed study publications.
Key coverage areas include advancements in circulating tumor DNA detection, expansions in reproductive health screening, and financial performance metrics. Bookmark this page to monitor how Natera's bioinformatics expertise continues influencing precision medicine across 150+ countries.
Natera (NASDAQ: NTRA) will present new data on its 385-gene kidney genetic test, Renasight™, at the American Society of Nephrology (ASN) Kidney Week 2024 in San Diego from Oct. 23-27. The company and collaborators will present 7 abstracts focused on comprehensive genetic testing for patients with chronic kidney disease (CKD).
This includes an updated analysis from the prospective RenaCARE study and additional data on the utility of genetic testing for CKD patients. The presentations align with recent support for renal genetic testing from organizations like NKF, KDIGO, and The New England Journal of Medicine.
Dr. Anthony Bleyer of Wake Forest University School of Medicine highlighted that 25% of dialysis patients don't know their kidney disease cause, emphasizing the importance of genetic testing. Natera's presentations will cover topics such as patient satisfaction with genetic counseling, genetic testing results in African American patients, and the genetic landscape of glomerular disease and FSGS.
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, has provided an update on its patent infringement litigation against NeoGenomics. On September 23, 2024, the District Court for the Middle District of North Carolina issued a permanent injunction against NeoGenomics' accused RaDaR assay, following a preliminary injunction from December 2023.
Natera is continuing to pursue its claim against a modified version of RaDaR for infringement of Natera's '454 patent. The company is seeking full remedies, including injunctive relief, especially after the Patent Office denied NeoGenomics' petition for 'inter partes' review challenging the validity of the '454 patent.
Natera (NASDAQ: NTRA) announced three new peer-reviewed publications for its Signatera test, surpassing 85 total publications. Key highlights include:
1. Colorectal cancer (CRC) data from the GALAXY arm of CIRCULATE-Japan, published in Nature Medicine and presented at ESMO 2024, showing Signatera's ability to predict overall survival and adjuvant chemotherapy benefit.
2. Additional CRC data from GALAXY, published in Annals of Oncology, demonstrating Signatera's ability to risk-stratify patients after liver metastases resection.
3. Breast cancer data from the BELLINI trial, published in Nature Medicine, exploring immune checkpoint inhibitors without chemotherapy in triple-negative breast cancer, with Signatera showing correlation to treatment response.
Natera, Inc. (NASDAQ: NTRA) announced new data from the GALAXY arm of the CIRCULATE-Japan trial at the 2024 ESMO Congress. The study, involving 2,240 patients with stage II-IV colorectal cancer, demonstrated Signatera's ability to predict overall survival (OS) and adjuvant chemotherapy (ACT) benefit. Key findings include:
1. Signatera-positive patients showed 9.68 times higher risk of death compared to Signatera-negative patients.
2. Signatera-positive patients receiving ACT had a 50% reduction in death risk.
3. Signatera status was the most significant predictor of recurrence across all pathologic stages.
4. Sustained Signatera clearance after ACT was associated with 100% 24-month OS.
These results highlight Signatera's potential to improve outcomes for colorectal cancer patients through personalized treatment decisions.
Natera will present new data on its Signatera molecular residual disease (MRD) test at the 2024 ESMO Congress. Key highlights include:
1. Data from the GALAXY arm of CIRCULATE-Japan trial, showing Signatera-positive patients had significantly shorter overall survival (OS) compared to Signatera-negative patients (hazard ratio ~10).
2. First prospective read-out of OS based on MRD in colorectal cancer (CRC).
3. New data on adjuvant chemotherapy (ACT) benefit in Signatera-positive and negative patients.
4. Additional presentations on Signatera in breast cancer and squamous cell carcinoma of the head and neck.
These findings underscore Signatera's potential to predict long-term outcomes and guide treatment decisions in early-stage CRC.
Natera, a leader in cell-free DNA and genetic testing, announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for Wednesday, Sept. 4 at 2:35 pm ET | 11:35 am PT in New York City. Natera's leadership team will be presenting at the conference.
Investors and interested parties can access a live webcast and audio archive of the presentation through the investor relations section of Natera's website at investor.natera.com. A replay of the event will be made available shortly after the conference concludes.
This participation highlights Natera's commitment to engaging with the investment community and showcasing its advancements in the field of genetic testing.
Natera (NASDAQ: NTRA), a leader in cell-free DNA and genetic testing, reported its Q2 2024 financial results.
Key highlights include total revenues of $413.4M, up 58.1% YoY, and product revenues of $411.4M, up 59.3%. Gross margin improved to 58.8% from 45.2%. The company processed approximately 760,300 tests, a 23.2% increase, including 125,400 oncology tests, a 50.2% increase. Natera achieved a positive cash flow of $3.3M.
Operating expenses rose to $287.1M, driven by headcount growth and increased consulting and legal costs. Net loss narrowed to $37.5M ($0.30/share) from $110.8M ($0.97/share) YoY. Natera's financial outlook for 2024 expects revenues between $1.49B and $1.52B, with a gross margin of 54%-56%.
The company launched a new feature for ProsperaTM Heart and presented new data at the ASCO 2024 Annual Meeting.
Natera, a leader in cell-free DNA testing, announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's leadership team will present on Wednesday, August 14 at 12:30 PM ET in Boston, MA. Investors and interested parties can access a live webcast of the event through Natera's investor relations website. For those unable to attend, a replay will be available shortly after the conference concludes.
This presentation offers an opportunity for investors to gain insights into Natera's current operations, future strategies, and potential growth prospects. As a key player in the cell-free DNA testing market, Natera's participation in this growth-focused conference may signal important developments or expansion plans for the company.
Natera (NASDAQ: NTRA), a leader in cell-free DNA testing, has announced it will release its second quarter 2024 financial results on August 8, 2024, after market close. The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results.
Interested parties can access the conference call via the following dial-in numbers:
- Domestic: 1-888-596-4144
- International: 1-646-968-2525
- Conference ID: 7684785
A webcast of the call will be available at https://events.q4inc.com/attendee/455235752, with a replay accessible later at investor.natera.com.
Natera, Inc. (NASDAQ: NTRA) has announced a new study published in the Journal of Clinical Oncology highlighting the utility of its Signatera test for surveillance in Merkel cell carcinoma (MCC). The prospective, multicenter study included 319 patients with stage I-IV MCC. Key findings show that Signatera demonstrated:
- Approximately 95% sensitivity for detecting clinically evident disease at enrollment
- Up to 20 times higher risk of recurrence in ctDNA-positive patients during surveillance
- 91% recurrence-free probability at 12 months for persistently ctDNA-negative patients
The study suggests that Signatera could become a standard monitoring tool in MCC, potentially reducing the frequency of surveillance imaging and guiding treatment decisions.